<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Digital Diagnostics</journal-id><journal-title-group><journal-title xml:lang="en">Digital Diagnostics</journal-title><trans-title-group xml:lang="ru"><trans-title>Digital Diagnostics</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Digital Diagnostics</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2712-8490</issn><issn publication-format="electronic">2712-8962</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">430330</article-id><article-id pub-id-type="doi">10.17816/DD430330</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Conference proceedings</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Материалы конференции</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>会议报告摘要</subject></subj-group><subj-group subj-group-type="article-type"><subject>Conference Abstract</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Telemedical follow-up in patients with inflammatory bowel diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Телемедицинское наблюдение у пациентов с воспалительными заболеваниями кишечника</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7705-9754</contrib-id><name-alternatives><name xml:lang="en"><surname>Akhmedzyanova</surname><given-names>Dina A.</given-names></name><name xml:lang="ru"><surname>Ахмедзянова</surname><given-names>Дина Альфредовна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dina_akhm@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8521-4045</contrib-id><name-alternatives><name xml:lang="en"><surname>Shumskaya</surname><given-names>Yuliya  F.</given-names></name><name xml:lang="ru"><surname>Шумская</surname><given-names>Юлия Федоровна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ashe.danny.jush@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9337-7453</contrib-id><name-alternatives><name xml:lang="en"><surname>Mnatsakanyan</surname><given-names>Marina  G.</given-names></name><name xml:lang="ru"><surname>Мнацаканян</surname><given-names>Марина Генриковна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mnatsakanyan08@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies</institution></aff><aff><institution xml:lang="ru">Научно-практический клинический центр диагностики и телемедицинских технологий</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-06-26" publication-format="electronic"><day>26</day><month>06</month><year>2023</year></pub-date><volume>4</volume><issue>1S</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>14</fpage><lpage>16</lpage><history><date date-type="received" iso-8601-date="2023-05-18"><day>18</day><month>05</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-05-18"><day>18</day><month>05</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><copyright-holder xml:lang="zh">Eco-Vector</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://jdigitaldiagnostics.com/DD/article/view/430330">https://jdigitaldiagnostics.com/DD/article/view/430330</self-uri><abstract xml:lang="en"><p>Inflammatory bowel diseases (IBDs) represent a group of nosologies including Crohn’s disease and ulcerative colitis. These diseases lead both to the deterioration of the patient’s physical condition and to a pronounced decrease in the quality of life. Currently, healthcare costs of managing patients with IBDs are steadily increasing and are commonly associated with the need for examinations and therapy with expensive drugs and unplanned expenses of healthcare resources for unscheduled consultations, emergency hospitalizations, and surgical interventions. Deterioration of patients’ condition may be associated with self-cancellation of therapy after normalization of the state of health. The use of telemedical technologies (TMTs) is promising for maintaining remission of IBDs, improving adherence to therapy, and reducing the frequency of unscheduled visits to the clinic and the cost of treating IBD complications (including surgery). The efficiency and benefits of TMTs in patients with IBDs were assessed in comparison with standard face-to-face follow-up. A literature search relevant to the review was conducted in the PubMed database. Papers were selected that assessed the efficiency of telemedical interventions among patients with IBDs as compared to the standard face-to-face follow-up group. The evaluation criteria included the degree of the disease activity, risks of IBD recurrence, quality of life of patients, adherence to therapy, healthcare costs, and frequency of visits to healthcare facilities. Telemedical interventions were conducted using the Internet, mobile applications, various telemedical platforms, SMS messages, and phone calls. The telemedical follow-up groups received access to educational materials and online consultations with a specialist upon request and completed questionnaires to assess disease activity, adherence to therapy, and quality of life. The degree of IBD activity and risk of recurrence and the level of adherence to therapy did not differ significantly between the telemedical intervention and standard face-to-face follow-up groups. The study by L. Pang et al. showed that the patients’ quality of life in the group of telemedical intervention was significantly higher (<italic>p</italic>=0.03) [8]. Another advantage of using TMTs is the provision of access to educational materials about IBDs and the possibility of remote contact with the treating physician. The patient’s ability to obtain necessary information reduces the need for unplanned visits to medical facilities and the cost of organizing medical care for patients with IBDs. The use of TMTs allows to monitor IBD activity as effectively as face-to-face follow-up, improve the patients’ quality of life with IBDs, and reduce costs for organizing care for patients with these diseases by decreasing the frequency of unscheduled visits to the doctor and conducting unnecessary additional examinations.</p></abstract><trans-abstract xml:lang="ru"><p>Воспалительные заболевания кишечника (ВЗК) — группа нозологий, включающая болезнь Крона и язвенный колит. Данные заболевания не только приводят к ухудшению соматического состояния пациента, но и выраженно снижают качество жизни. В настоящее время затраты здравоохранения на ведение пациентов с ВЗК неуклонно растут и часто ассоциированы не только с необходимостью проведения обследований и терапии дорогостоящими препаратами, но и c незапланированными расходами ресурсов здравоохранения: внеплановые консультации, экстренные госпитализации, хирургические вмешательства. Ухудшение состояния пациентов может быть связано в том числе и с самостоятельной отменой терапии на фоне нормализации самочувствия. Перспективным является применение телемедицинских технологий (ТМТ) для поддержания ремиссии ВЗК, улучшения приверженности терапии, снижения частоты внеплановых визитов в клинику и затрат на лечение осложнений ВЗК (в том числе хирургических). Проведена оценка эффективности и преимуществ использования ТМТ у пациентов с ВЗК в сравнении со стандартным очным наблюдением. Поиск литературы, соответствующей теме обзора, проводился в базе данных PubMed. Отобраны работы, в которых оценивалась эффективность телемедицинского вмешательства среди пациентов с ВЗК в сравнении с группой стандартного очного наблюдения. Критериями оценивания являлись: степень активности заболевания, риск рецидива ВЗК, качество жизни пациентов, приверженность терапии, затраты на здравоохранение и частота посещений медицинских учреждений. Телемедицинское вмешательство проводилось путём использования сети Интернет, мобильных приложений, различных телемедицинских платформ, SMS-сообщений и телефонных звонков. Группы телемедицинского наблюдения получали доступ к обучающим материалам, а также возможность онлайн-консультации со специалистом по запросу, проходили анкетирование по оценке активности заболевания, приверженности медикаментозной терапии, качества жизни и т.д. Степень активности и риск рецидива ВЗК, а также уровень приверженности терапии не имели существенных различий в группах телемедицинского вмешательства и стандартного очного наблюдения. В исследовании L. Pang и соавт. показано, что качество жизни пациентов в группе телемедицинского вмешательства было достоверно выше (p=0,03) [8]. Другим преимуществом использования телемедицинских технологий является предоставление доступа к обучающим материалам о ВЗК, а также возможность дистанционного контакта с лечащим врачом. Получение пациентом интересующей информации по мере необходимости уменьшает потребность во внеплановых посещениях медицинских учреждений, что в свою очередь снижает затраты на организацию медицинской помощи больным с ВЗК. Использование ТМТ позволяет контролировать активность ВЗК так же эффективно, как и очное наблюдение, улучшает качество жизни пациентов с ВЗК и позволяет уменьшить затраты здравоохранения на организацию помощи пациентам с указанными заболеваниями за счёт снижения частоты внеплановых посещений врача и проведения излишних дополнительных обследований.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>telemedicine</kwd><kwd>telemonitoring</kwd><kwd>eHealth</kwd><kwd>inflammatory bowel diseases</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>телемедицина</kwd><kwd>телемониторинг</kwd><kwd>eHealth</kwd><kwd>воспалительные заболевания кишечника</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat Rev Gastroenterol Hepatol. 2022;19(11):717–726. doi: 10.1038/s41575-022-00634-6</mixed-citation><mixed-citation xml:lang="ru">Bisgaard T.H., Allin K.H., Keefer L., Ananthakrishnan A.N., Jess T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment // Nat Rev Gastroenterol Hepatol. 2022. Vol. 19, N 11. P. 717–726. doi: 10.1038/s41575-022-00634-6</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Singh S, Qian AS, Nguyen NH, et al. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996–2016. Inflamm Bowel Dis. 2022;28(3):364–372. doi: 10.1093/ibd/izab074</mixed-citation><mixed-citation xml:lang="ru">Singh S., Qian A.S., Nguyen N.H., et al. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996–2016 // Inflamm Bowel Dis. 2022. Vol. 28, N 3. P. 364–372. doi: 10.1093/ibd/izab074</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. Clin Gastroenterol Hepatol. 2018;16(8):1284–1292.e30. doi: 10.1016/j.cgh.2018.02.015</mixed-citation><mixed-citation xml:lang="ru">Nguyen N.H., Khera R., Ohno-Machado L., Sandborn W.J., Singh S. Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases // Clin Gastroenterol Hepatol. 2018. Vol. 16, N 8. P. 1284–1292.e30. doi: 10.1016/j.cgh.2018.02.015</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Keil R, Wasserbauer M, Zádorová Z, et al. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol. 2018;53(4):459–465. doi: 10.1080/00365521.2018.1451915</mixed-citation><mixed-citation xml:lang="ru">Keil R., Wasserbauer M., Zádorová Z., et al. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study // Scand J Gastroenterol. 2018. Vol. 53, N 4. P. 459–465. doi: 10.1080/00365521.2018.1451915</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Davis SP, Ross MSH, Adatorwovor R, Wei H. Telehealth and mobile health interventions in adults with inflammatory bowel disease: A mixed-methods systematic review. Res Nurs Health. 2021;44(1):155–172. doi: 10.1002/nur.22091</mixed-citation><mixed-citation xml:lang="ru">Davis S.P., Ross M.S.H., Adatorwovor R., Wei H. Telehealth and mobile health interventions in adults with inflammatory bowel disease: A mixed-methods systematic review // Res Nurs Health. 2021. Vol. 44. N 1. P. 155–172. doi: 10.1002/nur.22091</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Fiorino G, Allocca M, Chaparro M, et al. ‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019;13(1):127–137. doi:10.1093/ecco-jcc/jjy140</mixed-citation><mixed-citation xml:lang="ru">Fiorino G., Allocca M., Chaparro M., et al. ‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review // J Crohns Colitis. 2019. Vol. 13, N 1. P. 127–137. doi: 10.1093/ecco-jcc/jjy140</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Nguyen NH, Martinez I, Atreja A, et al. Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol. 2022;117(1):78–97. doi: 10.14309/ajg.0000000000001545</mixed-citation><mixed-citation xml:lang="ru">Nguyen N.H., Martinez I., Atreja A., et al. Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review // Am J Gastroenterol. 2022. Vol. 117, N 1. P. 78–97. doi: 10.14309/ajg.0000000000001545</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Pang L, Liu H, Liu Z, et al. Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Med Internet Res. 2022;24(3):e28978. doi: 10.2196/28978</mixed-citation><mixed-citation xml:lang="ru">Pang L., Liu H., Liu Z., et al. Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials // J Med Internet Res. 2022. Vol. 24, N 3. P. e28978. doi: 10.2196/28978</mixed-citation></citation-alternatives></ref></ref-list></back></article>
